Servier Pharmaceuticals

What Servier Pharmaceuticals does

Servier Pharmaceuticals LLC is the U.S. commercial subsidiary of Servier Group (Les Laboratoires Servier), a global pharmaceutical company founded in France in 1952 and governed by a non-profit foundation headquartered in Suresnes, France. Servier Group reported consolidated revenue of €5.9 billion in 2023, up from €4.9 billion in 2022, and employed approximately 21,900 people globally, distributing medicines in roughly 150 countries. The U.S. subsidiary was established in February 2018 with the opening of its Boston office and has grown primarily through strategic acquisitions including Shire's oncology business (2018), PIXUVRI from CTI BioPharma (2019), Agios Pharmaceuticals' oncology business (2021, up to $2 billion), and Day One Biopharmaceuticals (2026, $2.5 billion).

Servier's commercial portfolio centers on targeted oncology and rare disease therapies, anchored by its leadership in mutant IDH inhibition. Approved products include VORANIGO (vorasidenib), the first targeted therapy for Grade 2 IDH-mutant glioma (FDA-approved August 2024); TIBSOVO (ivosidenib), an IDH1 inhibitor approved across AML, cholangiocarcinoma, and MDS; OJEMDA (tovorafenib) for pediatric low-grade glioma acquired through Day One; ONIVYDE for metastatic pancreatic adenocarcinoma; and Asparlas for acute lymphoblastic leukemia. The company allocates over 65% of its R&D budget to oncology and operates a pipeline of 44 active oncology and neurology programs spanning research, early development, and late development stages. Servier runs a Phase III PyramIDH trial in partnership with Tempus TIME sites for IDH1-mutated MDS and pursues additional programs including CLDN18.2-targeted therapies in solid tumors.

The business model is commercial-stage branded pharmaceutical sales through specialty pharmacy distribution, hospital and cancer center direct sales in the U.S., and international distribution partnerships across 150+ countries. Revenue is generated through one-time product sales and licensing/royalty arrangements, including royalties on TIBSOVO following the Agios transaction. Go-to-market relies on a U.S. field sales force targeting oncologists and hematologists, active presence at major medical congresses (ASCO, ASH, SNO, EHA), medical affairs engagement with key opinion leaders, and patient support programs. The foundation-governed ownership structure differentiates Servier from investor-driven pharma by enabling sustained R&D investment in small, hard-to-treat patient populations where economic returns are constrained by rarity.

Name

Servier Pharmaceuticals

Legal name

Servier Pharmaceuticals LLC

Website

https://servier.us

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

251–500 employees

Short description

Servier Pharmaceuticals is the U.S. subsidiary of foundation-governed Servier Group, commercializing targeted oncology and neurology therapies with category leadership in mutant IDH inhibition, including VORANIGO, TIBSOVO, and OJEMDA for rare cancers.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Targeted oncology therapies
• IDH mutation inhibitors
• Pharmaceutical drug development
• Precision medicine oncology
• Rare disease treatments

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Product Sales: Servier generates revenue through direct commercial sales of branded pharmaceutical products in oncology and other therapeutic areas. The company markets targeted therapies for IDH-mutated cancers and other difficult-to-treat tumors through its U.S. commercial organization.
2. Generic Pharmaceuticals: Servier also generates revenue from a portfolio of quality generic drugs covering most pathologies, with strong brands in France, Eastern Europe, Brazil, and Nigeria.
3. Royalty and Licensing: Following the Agios acquisition, Servier owns global rights to TIBSOVO and receives royalties from licensing arrangements in various territories.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Servier Pharmaceuticals is a U.S. commercial-stage pharmaceutical company that develops, manufactures, and commercializes branded targeted therapies for oncology and neurology, with a primary focus on IDH-mutant cancers. The company's core products include VORANIGO (vorasidenib) for Grade 2 IDH-mutant glioma, TIBSOVO (ivosidenib) for IDH1-mutated AML, cholangiocarcinoma, and MDS, and OJEMDA (tovorafenib) for pediatric low-grade glioma. It supplements drug sales with biomarker testing services, clinical trial programs, and patient support services.

Product overview

Servier Pharmaceuticals is a global pharmaceutical company and U.S. commercial subsidiary governed by a non-profit foundation, with a focus on oncology and neurology. The company's product portfolio centers on targeted therapies for cancers with IDH mutations (IDH1/IDH2), with VORANIGO (vorasidenib) as the first approved targeted therapy for Grade 2 IDH-mutant glioma and TIBSOVO (ivosidenib) approved across multiple IDH1-mutated cancers including AML, cholangiocarcinoma, and MDS. Servier has expanded through acquisitions including Agios Pharmaceuticals' oncology business (gaining TIBSOVO and vorasidenib), Shire's oncology business (gaining ONIVYDE), and Day One Biopharmaceuticals (gaining OJEMDA for pediatric low-grade glioma). The company also offers diagnostic testing services to identify IDH mutations and conducts extensive clinical trials through partnerships with research institutions. Key products span hematologic malignancies (AML, MDS, ALL, non-Hodgkin lymphoma) and solid tumors (glioma, cholangiocarcinoma, pancreatic cancer, colorectal cancer). Servier allocates over 65% of its R&D budget to oncology and operates a One Innovation Engine approach combining internal development with strategic partnerships and acquisitions.

Differentiator

Problem solved

Functional benefit

Products and services

• VORANIGO (vorasidenib) Oral, targeted dual inhibitor of mutant IDH1/2 enzymes approved by the FDA as the first targeted therapy for Grade 2 IDH-mutant diffuse glioma. Demonstrated improved progression-free survival and tumor reduction in the Phase 3 INDIGO trial.
• TIBSOVO (ivosidenib tablets) Oral targeted IDH1 inhibitor approved for multiple IDH1-mutated cancers including newly diagnosed and relapsed/refractory AML (as monotherapy or with azacitidine), previously treated cholangiocarcinoma, and relapsed/refractory MDS.
• OJEMDA (tovorafenib) FDA-approved targeted therapy for treating pediatric low-grade glioma (pLGG), acquired by Servier through the $2.5 billion acquisition of Day One Biopharmaceuticals in April 2026.
• Asparlas (calaspargase pegol) Asparaginase product used in the treatment of acute lymphoblastic leukemia (ALL), particularly in pediatric oncology programs.
• PIXUVRI (pixantrone) Treatment for non-Hodgkin B-cell lymphoma acquired by Servier from CTI BioPharma, strengthening the Servier oncology portfolio.
• ONIVYDE Treatment for metastatic pancreatic adenocarcinoma approved in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as first-line therapy; received positive CHMP opinion for EU approval.
• LONSURF (trifluridine and tipiracil) Colorectal cancer treatment co-promoted with Taiho Oncology.
• IDH Mutation Testing Services Biomarker testing services to identify IDH1 and IDH2 mutations in cancer patients, enabling personalized treatment approaches with targeted therapies like TIBSOVO and VORANIGO.
• PyramIDH Clinical Trial Phase III clinical trial investigating ivosidenib (TIBSOVO) for IDH1-mutated newly diagnosed MDS patients, partnering with Tempus TIME sites in the U.S.

Quantifiable outcome

• Vorasidenib demonstrated median PFS of 27.7 months vs 11.1 months placebo (HR 0.39) in Phase 3 INDIGO trial for IDH-mutant glioma
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and supporting.

• Day One BiopharmaceuticalscoreStrategic or Co-development Partner · 23 April 2026Servier completed acquisition of Day One Biopharmaceuticals for $2.5 billion, gaining access to FDA-approved OJEMDA for pediatric low-grade glioma and broader rare oncology pipeline assets. The transaction was completed via cash tender offer at $21.50 per share with approximately 85.34% of shares tendered.
• CStone PharmaceuticalssupportingStrategic or Co-development Partner · 21 December 2023Servier acquired from CStone the exclusive rights to develop and commercialize TIBSOVO in Greater China (including mainland, Hong Kong, Macau, and Taiwan) and Singapore for $44 million plus up to $6 million upon completion. CStone had previously held these rights under license from Servier.
• Agios PharmaceuticalscoreStrategic or Co-development Partner · 1 April 2021Servier completed acquisition of Agios Pharmaceuticals' oncology business for up to $2 billion plus royalties. This acquisition gave Servier global rights to TIBSOVO (ivosidenib) and vorasidenib, establishing Servier as a leader in IDH-mutant targeted therapies.
• Precision BioSciencessupportingStrategic or Co-development Partner · 22 December 2020Collaboration to explore immune checkpoint signaling in cancer research, focusing on novel therapeutic approaches.
• Celsius TherapeuticssupportingStrategic or Co-development Partner · 22 December 2020Target discovery collaboration in colorectal cancer, combining Servier's oncology expertise with Celsius's platform capabilities.
• Shire PharmaceuticalscoreStrategic or Co-development Partner · 21 December 2020Servier acquired Shire's oncology business in 2018 to gain direct commercial access in the U.S. market, establishing foundational U.S. commercial presence.
• CureMatchsupportingTechnology or Integration · 12 October 2020Launch of Bionov clinical decision support software, a CE-marked digital health tool to support precision medicine treatment decisions in oncology.
• TempussupportingTechnology or IntegrationPartnership with Tempus TIME sites for the PyramIDH clinical trial in the U.S. Tempus provides site locations and capabilities for IDH1-mutated MDS clinical trial enrollment.
• Base4 BiotechnologysupportingStrategic or Co-development PartnerServier expanded partnership with Base4 to advance neuroscience drug development, building on initial collaboration to leverage AI and novel drug discovery approaches.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca: AstraZeneca has a substantial oncology franchise (Tagrisso, Imfinzi, Enhertu, Calquence, Lumoxiti via Alexion) and rare disease capabilities through Alexion. Its broad oncology portfolio with rare-disease specialty exposure makes it a relevant broad incumbent peer for Servier's commercial-stage positioning.
• Daiichi Sankyo: Daiichi Sankyo is a Japanese-headquartered global pharmaceutical company with a major oncology franchise (DS-8201/Enhertu ADC platform). Its European roots via the Ranbaxy integration and broad oncology pipeline make it a broad incumbent peer in targeted oncology.
• Pfizer: Pfizer is a global oncology leader with a deep targeted oncology pipeline (including Seagen-acquired ADCs) and established rare-disease hematology presence. As a broad incumbent across all of Servier's oncology indications, Pfizer represents the scale benchmark against which Servier's specialty franchise is valued.

Direct peers

• Bristol-Myers Squibb: BMS markets IDHIFA (enasidenib), a direct IDH2 inhibitor competitor to Servier's TIBSOVO (ivosidenib) in IDH-mutated AML. As a global oncology major, BMS provides the closest competitive benchmark for Servier's IDH franchise.
• Blueprint Medicines: Blueprint Medicines is a precision oncology company focused on genomically-defined rare cancers and rare disease (AYVAKIT, GAVRETO). Its biomarker-driven development model and rare-disease commercial focus closely mirror Servier's IDH-mutant franchise strategy.
• Jazz Pharmaceuticals: Jazz is a specialty pharmaceutical company with a strong hematology/oncology franchise (Vyxeos for AML, Erwinaze for ALL). Its focus on rare and difficult-to-treat cancers with field-force commercial models closely parallels Servier Pharmaceuticals' commercial-stage specialty oncology strategy.
• Incyte Corporation: Incyte is a specialty oncology company with marketed hematology/oncology assets (Jakavi, Iclusig, Pemazyre, Opzelura) and a strong R&D engine. Its focus on myeloproliferative neoplasms and rare cancers makes it a directly comparable specialty oncology peer.
• Agios Pharmaceuticals: Agios sold its oncology business (including TIBSOVO and vorasidenib) to Servier in 2021, and retains a hematology/cell therapy focus (mitapivat for hemolytic anemias). It remains a directly comparable rare disease oncology peer from which Servier acquired core assets.
• Ipsen: Ipsen is a European-headquartered specialty pharmaceutical company with a significant oncology franchise (Somatuline, TAFINLAR in selected markets). Its continental European base, specialty pharma model, and oncology focus make it one of the closest pure-play structural analogs to Servier.

Others

• Taiho Oncology: Taiho Oncology is Servier's co-promotion partner for LONSURF (trifluridine/tipiracil) in colorectal cancer. As a Japanese-affiliated oncology company and active commercial-stage ecosystem partner, Taiho represents an adjacent commercial peer rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ServierPharma
• YouTubeyoutube.com/channel/UCun9xf_0VForXzW85JoK0cw
• LinkedInlinkedin.com/company/servier-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Pharmaceuticals